Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

T-Cell p16 INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma

Ashley E. Rosko, MD, Craig C Hofmeister, MD MPH, Don Benson, MD PhD, Yvonne A Efebera, MD, Ying Huang, MA, MS, Christin Burd, PhD

Blood (2014) 124 (21): 2023.

https://doi.org/10.1182/blood.V124.21.2023.2023

Published: 2014

Journal Articles

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Rhonda Kitzler, BS, Patrick Elder, MS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Kevin Coombes, PhD, Craig C Hofmeister, MD MPH, Don Benson, MD PhD, Steven M. Devine, MD, Gerard Lozanski, MD

Blood (2014) 124 (21): 1166.

https://doi.org/10.1182/blood.V124.21.1166.1166

Published: 2014

Journal Articles

2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

Douglas W. Sborov, MD, Misty Lamprecht, CNS, Don Benson, MD PhD, Karen Tackett, RN, Yvonne A Efebera, MD, Rosko E Ashley, MD, Steven M. Devine, MD, Ming Poi, PharmD, PhD, Mitch A. Phelps, PhD, Craig C Hofmeister, MD MPH

Blood (2014) 124 (21): 3960.

https://doi.org/10.1182/blood.V124.21.3960.3960

Published: 2014

Journal Articles

p53-Inducible Micrornas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.

Flavia Pichiorri, PhD, MSC, Sung-Suk Suh, Luciana De Luca, Cristian Taccioli, Don Benson, MD, PhD, Craig Hofmeister, MD, Rami Aqeilan, Carlo M. Croce, MD

Blood (2009) 114 (22): 1973.

https://doi.org/10.1182/blood.V114.22.1973.1973

Published: 2009

Journal Articles

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

Don Benson, MD, PhD, Courtney E Bakan, Lana Alghothani, Craig C. Hofmeister, MD, Yvonne A Efebera, M.D., Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Steven M Devine, MD

Blood (2009) 114 (22): 4641.

https://doi.org/10.1182/blood.V114.22.4641.4641

Published: 2009

Journal Articles

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

Farrukh Awan, MD, MS, Rosa Lapalombella, PhD, Rossana Trotta, PhD, Jonathan P Butchar, Ph.D., Bo Yu, Don Benson, MD, PhD, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Alan Jones, MD, MPH, Joseph M Flynn, David Jarjoura, Robert A. Baiocchi, MD, PhD, John Desjarlais, Susheela Tridandapani, Ph.D., Michael A. Caligiuri, M.D., Natarajan Muthusamy, PhD, John C. Byrd

Blood (2009) 114 (22): 3725.

https://doi.org/10.1182/blood.V114.22.3725.3725

Published: 2009

Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 3870.

https://doi.org/10.1182/blood.V114.22.3870.3870

Published: 2009

Journal Articles

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Don Benson, MD, PhD, Craig C. Hofmeister, MD, Swaminathan Padmanabhan, MD, MBBS, Rafat Abonour, Attaya Suvannasankha, MD, Alain Mita, Patrick Squiban, MD, Megan K Smith, MS, CNP, RN, Courtney E Bakan, Marc Marzetto, Pascale Andre, PhD, Jerome Tollier, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 2880.

https://doi.org/10.1182/blood.V114.22.2880.2880

Published: 2009

Journal Articles

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.

Craig C Hofmeister, M.D., Don Benson, MD, PhD, Yvonne A Efebera, M.D., Sherif Farag, MBBS, PhD, Michael R. Grever

Blood (2009) 114 (22): 2884.

https://doi.org/10.1182/blood.V114.22.2884.2884

Published: 2009

Journal Articles

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Spero R. Cataland, MD, Eric H. Kraut, MD, Don Benson, MD, PhD, Amy K. Ferketich, PhD, April Horne, Ming Jin, PhD, James N. George, MD, Haifeng M. Wu, MD

Blood (2006) 108 (11): 1056.

https://doi.org/10.1182/blood.V108.11.1056.1056

Published: 2006

NARROW

T-Cell p16 INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial

p53-Inducible Micrornas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.

Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.

CD19 Targeting of Lymphoid Malignancies by Novel Fc-Domain Engineered Monoclonal Antibody.

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.

Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only